Recent News

• 05.13.2025 - ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
• 05.13.2025 - ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
• 05.06.2025 - Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis
• 05.06.2025 - Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis
• 05.01.2025 - ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis
• 05.01.2025 - ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis
• 04.21.2025 - Alumis and ACELYRIN Announce Amended Merger Agreement
• 04.21.2025 - Alumis and ACELYRIN Announce Amended Merger Agreement

Recent Filings

• 05.06.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 05.06.2025 - 425 Prospectuses and communications, business combinations
• 05.01.2025 - 425 Prospectuses and communications, business combinations
• 04.30.2025 - SCHEDULE 13D General Statement of Acquisition of Beneficial Ownership
• 04.29.2025 - 425 Prospectuses and communications, business combinations
• 04.29.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 04.23.2025 - DEFR14A Revised definitive proxy soliciting materials
• 04.21.2025 - 8-K Current report
• 04.21.2025 - EX-99.1 EX-99.1
• 04.21.2025 - 425 Prospectuses and communications, business combinations